You have read all your free articles, to continue reading subscribe to read the rest of this content.
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) is baAlready a subscriber Login You have read all…
Ilya Pharma is one of ten life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science. The company joins over 800 experienced “been there, run that” entrepreneurs who make up the Springboard Alumnae Network, it states in its press release. ThisAlready a subscriber Login You have…
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share eqAlready a subscriber Login You have read all your…
Immedica Pharma has announced that RAVICTI has been accepted and granted Priority Review for the New Drug Application (NDA) in China. In April, another submission for RAVICTI Market Authorisation Approval was accepted by the Department of Health (DoH) in HongKong. “With these submissions inAlready a subscriber Login You have read all…
